State of the Art in HCC: Immune Checkpoint Modulation

Slides:

Advertisements

Similar presentations

Brian Boulmay, MD LSUHSC- New Orleans Section of Hematology & Oncology

Advertisements

Advancing Care Forward in Squamous Cell Carcinoma of the Head and Neck

advanced lung adenocarcinoma subtype

Bladder Cancer: A New Era in Treatment

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Evolving Paradigms in Recurrent/Metastatic SCCHN

Nat. Rev. Clin. Oncol. doi: /nrclinonc

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

Treatment Algorithms in Melanoma: Past, Present, and Future

Program Goals. Clinical Considerations in the Use of Checkpoint Inhibitors for Gastrointestinal Cancers.

Advanced NSCLC Without Actionable Mutations

New Patient Journeys in Non-small cell lung cancer

Essential Concepts in Harnessing the Immune System in Head and Neck Cancer.

Immunotherapy Combinations for Lung Cancers

Spotlight on Immuno-Oncology in Melanoma

REFLECT: First-Line Lenvatinib vs Sorafenib in HCC Study Design

Metastatic Renal Cell Carcinoma

Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.

Updates in Lung Cancer: Insights From Vienna

Optimizing the Treatment of Recurrent/Metastatic SCCHN

Activity Goals. Activity Goals Discussion Topics.

Program Goals Introduction Case 1: A 44-Year-Old Woman.

Management of Glioblastoma

The Evolving Role of Immunotherapy in NSCLC

Immunotherapy in Pancreatic Cancer: Thinking Outside the Box

Optimizing Management of Advanced Bladder Cancer

Basics of Immunotherapy Potential Therapeutic Targets.

Treating mRCC After Initial Antiangiogenic Therapy:

Advanced Lung Cancers: What's on the Horizon?

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

Presented By Johanna Bendell at 2016 ASCO Annual Meeting

Case Studies in Unresectable Hepatocellular Carcinoma

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Nat. Rev. Urol. doi: /nrurol

Immunotherapy for cSCC

Advancing Care in Genitourinary Cancer: Perspectives From Chicago

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

Evolving Concepts in the Management of Head and Neck Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

Locally Advanced Lung Cancer

Advances in Gastrointestinal Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Changing the Paradigm of Treatment in Patients With Hodgkin Lymphoma

This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.

Novel Concepts in the Management of RCC

Debates and Dilemmas, Part 1

From Adjuvant to Metastatic in Melanoma

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

Activity Goals. Clinical Considerations in the Use of Checkpoint Inhibitors for Genitourinary Cancers.

Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer.

Taking a Closer Look at Recurrent/Metastatic SCCHN

Going Beyond EXTREME in Head and Neck Cancer

Moving Care Forward in Advanced Gastric Cancer

New Options for the Treatment of Hepatocellular Carcinoma

Current Status of Biomarkers for Immune Checkpoint Inhibitors

Immune Checkpoint Inhibitors in Lung Cancer

Combining Immunotherapy and Chemotherapy in NSCLC

The Nurse View.

The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Recent Developments in the Treatment of Advanced and Metastatic RCC

Presentation transcript:

State of the Art in HCC: Immune Checkpoint Modulation

Hepatocellular Carcinoma Background

Immune Checkpoint Modulation in HCC

Standard of Care for HCC First-Line and Second-Line Treatments

Investigational Agents Lenvatinib in HCC

Tremelimumab: Phase 2 Study in HCV Associated HCC Cohort

Tremelimumab: Phase 2 Study Results

Checkpoint Inhibitors: PD-1/PD-L1

Nivolumab Phase 1/2 Dose-Escalation and Expansion: CheckMate 040 Study

CheckMate 040: Phase 1 and 2 Overall Results

CheckMate 040: Phase 1 and 2 Individual Results

KEYNOTE-224: Pembrolizumab in Previously Treated Advanced HCC

KEYNOTE-240: Pembrolizumab vs BSC for Second-Line Advanced HCC

Phase 1 Durvalumab in Multiple Solid Tumor Types

Phase 1/2: Durvalumab and Tremelimumab as Monotherapy and in Combination with Unresectable HCC

Atezolizumab Plus Bevacizumab in Solid Tumors

CheckMate 459 Nivolumab vs Sorafenib

CheckMate-040 Safety Data

AE Management Issues

Predictive Biomarkers for Response to Immunotherapy

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)